



# Novel Oral Polio Vaccine type 2 (nOPV2) in Support of Polio Eradication Initiative

Iin Susanti  
Production & Supply Chain Director  
PT Bio Farma, Indonesia

25<sup>th</sup> DCVMN Annual General Meeting  
October 16 -18 , 2024  
São Paulo, Brazil

# Novel Oral Polio Vaccine Type 2 (nOPV2)



## nOPV2 key milestones:

- The development was started in 2014 supported by BMGF-PATH
- EUL in 2020 (the first ever vaccine licensed under EUL)
- SAGE recommended it as the preferred option for cVDPV2 outbreak response in 2023
- WHO prequalification (PQ) in 2023

## Deployment:

Approx. 1 billion doses has been distributed under EUL to respond outbreak in more than 33 countries

## Global supply commitment:

Bio Farma performs tech transfer to Biological E (WHO PQ in 2024)

## Significance:

Overall decline in trend of new emergence (and number of cases, countries infected) in recent past was observed, especially following wide-scale use of nOPV2

## Key success factor:

International collaborations contributed significantly to the development and production of the novel polio vaccine



## Acknowledgment



# Bio Farma's Roles in Supporting Polio Eradication Strategy

## Polio eradication strategy


- Goal 1: **Interrupt** all Poliovirus transmission in endemic countries
- Goal 2: **Stop transmission** of variant Poliovirus and prevent outbreaks in non-endemic countries (GPEI)

## Vaccination

has been the most cost-effective modality for preventing polio infection and transmission

## Bio Farma's contribution

- Supply of bOPV
- Supply of nOPV2
- Development of nOPV1,3 supported by BMGF
- Development of VLP-based IPV in collaboration with Cansino



# Thank You

Stay connected with Biofarma Group



This document is exclusively intended for selected client employees. Distribution, quotations, and duplications - even in the form of extracts - for third parties is only permitted upon prior written consent of Biofarma Group.

Biofarma Group used the text and charts compiled in this report in a presentation; they do not represent a complete documentation of the presentation.

© October 2024 | Biofarma Group  
Confidential & Proprietary

